IRB #

STUDY00015649

Title

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Principal Investigator

Lara Davis

Study Purpose

The purpose of this study is to test any good and bad effects of a study drug called tazemetostat on participants with one of the following types of cancers - rhabdoid tumor, synovial sarcoma, and INI1 tumors.

Medical Condition(s)

Rhabdoid tumor, synovial sarcoma, INI1 tumors

Eligibility Criteria

Must be 18 years or older. Tests and procedures including blood tests, scanning, and a routine physical will be done before you can start to study to see if you are eligible.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drug for as long as you are seeing clinical benefit. We will continue to follow up with participants by phone every 3 months for the rest of their lives.

Minors Included

Yes

Contact

Sierra Bertolone-Smith
bertolon@ohsu.edu
503-494-0824

Sponsor

Epizyme, Inc.

Recruitment End

02/29/2020

Compensation Provided

No


Go Back